SARC033

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

TYPE OF SARCOMA: Epithelioid Hemangioendothelioma
DRUG: Trametinib

ACCRUAL STATUS: Not recruiting

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Scott Schuetze, MD, PhD
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center EDDOP

CLINICALTRIALS.GOV IDENTIFIER: NCT03148275

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV